Literature DB >> 17885583

Expression of nm23-H1 in uveal melanoma.

Silvin Bakalian1, Jean Claude Marshall, Dana Faingold, Patrick Logan, Emilia Antecka, Miguel N Burnier.   

Abstract

Uveal melanoma (UM) is the most common malignant intraocular tumor in adults. Despite the high accuracy of clinical diagnosis and advances in local treatment, more than 50% of UM patients develop metastasis within 10 years of initial diagnosis. NM23 is one of the human metastasis suppressor genes. Reduced nm23-H1 expression is correlated with high metastatic potential in many different cancers. The purpose of this study is to investigate the expression of nm23-H1 in UM and its potential value as a prognostic marker. Immunostaining of nm23-H1 was verified in five human UM cell lines with different metastatic potentials. The expression level of nm23-H1 mRNA was evaluated with one-step quantitative real-time PCR. The invasion ability of the cell lines was assessed before and after silencing nm23-H1 with small interference RNA. Thirty-two cases of paraffin-embedded specimens of human UM were immunostained with nm23-H1 monoclonal antibody. The immunostaining was evaluated in a semiquantitative fashion based on extent and intensity. The real-time PCR results of five human UM cell lines showed that expression of nm23-H1 was higher in cell lines with low metastatic potential compared with those with high metastatic potential (P<0.05). The invasive ability of the UM cell lines increased after silencing nm23-H1 expression with small interference RNA (P<0.05). The immunostaining of nm23-H1 was cytoplasmic in all cell lines and UM patients samples. The increased immunostaining intensity of nm23-H1 in patients' samples was associated with better survival rate (Kaplan-Meier test P=0.0097). The expression of nm23-H1 was not correlated with other prognostic factors. It can be concluded that nm23-H1 may be a prognostic marker to predict the survival rate of UM patients and it has the potential to identify high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885583     DOI: 10.1097/CMR.0b013e3282eeea5a

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  4 in total

Review 1.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

Review 2.  Learning about the functions of NME/NM23: lessons from knockout mice to silencing strategies.

Authors:  Mathieu Boissan; Marie-Lise Lacombe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-12       Impact factor: 3.000

3.  The NDPK/NME superfamily: state of the art.

Authors:  Mathieu Boissan; Uwe Schlattner; Marie-Lise Lacombe
Journal:  Lab Invest       Date:  2018-02       Impact factor: 5.662

4.  Expression of the metastasis suppressor BRMS1 in uveal melanoma.

Authors:  Bruna V Ventura; Carlos Quezada; Shawn C Maloney; Bruno F Fernandes; Emilia Antecka; Claudia Martins; Silvin Bakalian; Sebastian di Cesare; Miguel N Burnier
Journal:  Ecancermedicalscience       Date:  2014-03-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.